Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Frank Mross"'
Autor:
Markus Zuber, Frank Mross, Sören Kneif, Karl-Ludwig Schaefer, Christopher Poremba, Andreas Schuck, Agnes Bankfalvi, Franz Fogt, Bernhard Heine, Yvonne Braun, Joachim Torhorst, Harald Stein, Daniel H. Wai, Raihanatou Diallo, Werner Boecker, O.R. Köchli, C Lanvers, Holger Dieterich, Achim Heinecke, Guido Sauter
Publikováno v:
The Journal of Pathology. 198:181-189
Telomerase activity (TA) has been shown to correlate with poor clinical outcome in various tumour entities, indicating that tumours expressing this enzyme may be more aggressive and that TA may be a useful prognostic marker. For breast cancer, howeve
Autor:
David Botstein, Guido Sauter, Rob Seitz, Olli Kallioniemi, Matt van de Rijn, Juha Kononen, Phillippe Haas, Doug Ross, Joachim Torhorst, Charles M. Perou, Robert Tibshirani, O.R. Köchli, Holger Dieterich, Patrick O. Brown, Markus Zuber, Frank Mross
Publikováno v:
The American journal of pathology. 161(6)
While several prognostic factors have been identified in breast carcinoma, the clinical outcome remains hard to predict for individual patients. Better predictive markers are needed to help guide difficult treatment decisions. In a previous study of
Autor:
Christopher, Poremba, Bernhard, Heine, Raihanatou, Diallo, Achim, Heinecke, Daniel, Wai, Karl-Ludwig, Schaefer, Yvonne, Braun, Andreas, Schuck, Claudia, Lanvers, Agnes, Bànkfalvi, Sören, Kneif, Joachim, Torhorst, Markus, Zuber, Ossi R, Köchli, Frank, Mross, Holger, Dieterich, Guido, Sauter, Harald, Stein, Franz, Fogt, Werner, Boecker
Publikováno v:
The Journal of pathology. 198(2)
Telomerase activity (TA) has been shown to correlate with poor clinical outcome in various tumour entities, indicating that tumours expressing this enzyme may be more aggressive and that TA may be a useful prognostic marker. For breast cancer, howeve
Autor:
Philippe Haas, Markus Zuber, Guido Sauter, Joachim Torhorst, Holger Moch, Frank Mross, O.R. Köchli, Olli-P. Kallioniemi, Holger Dieterich, Christoph Bucher, Michael J. Mihatsch, Juha Kononen
Advances in genomics and proteomics are dramatically increasing the need to evaluate large numbers of molecular targets for their diagnostic, predictive or prognostic value in clinical oncology. Conventional molecular pathology techniques are often t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5a72a521fdb8e634e39f2b5884bd661
https://europepmc.org/articles/PMC1850582/
https://europepmc.org/articles/PMC1850582/